2864 Defining 131I-refractory differentiated thyroid cancer: efficacy and safety of lenvatinib by 131I-refractory criteria in the SELECT trial. (September 2015) - Kiyota, N.; Robinson, B.; Shah, M.; Hoff, A.O.; Taylor, M.; Li, D.; Dutcus, C.; Lee, E.K.; Kim, S.B.; Tahara, M.